Cardiovascular considerations in antidepressant therapy: An evidence-based review

Journal of Tehran University Heart Center

Volumn 8, Issue 4, 2013, Pages 169-176

  Yekehtaz, Habibeh ^a   Farokhnia, Mehdi ^a   Akhondzadeh, Shahin ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Antidepressive agents; Cardiovascular diseases; Depressive disorder; Major

Indexed keywords

AMITRIPTYLINE; AMOXAPINE; ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; DESIPRAMINE; DESVENLAFAXINE; DOXEPIN; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; IMIPRAMINE; MAPROTILINE; MIRTAZAPINE; MOCLOBEMIDE; NORTRIPTYLINE; PAROXETINE; PHENELZINE; REBOXETINE; SELEGILINE; SERTRALINE; TRANYLCYPROMINE; TRAZODONE; VENLAFAXINE;

ACUTE CORONARY SYNDROME; ADVERSE OUTCOME; ATRIOVENTRICULAR BLOCK; BRADYCARDIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DEPRESSION; DRUG EFFICACY; DRUG OVERDOSE; DRUG SAFETY; ECG ABNORMALITY; ELECTROLYTE DISTURBANCE; FAINTNESS; HEART ARRHYTHMIA; HEART BUNDLE BRANCH BLOCK; HEART FAILURE; HEART INFARCTION; HEART LEFT BUNDLE BRANCH BLOCK; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE ISCHEMIA; HEART RIGHT BUNDLE BRANCH BLOCK; HEART VENTRICLE EXTRASYSTOLE; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; HYPERTENSION; HYPERTENSIVE CRISIS; HYPOKALEMIA; HYPOMAGNESEMIA; HYPOTENSION; LONG QT SYNDROME; MYOCARDITIS; ORTHOSTATIC HYPOTENSION; OUTCOME ASSESSMENT; QT PROLONGATION; REENTRY ARRHYTHMIA; REVIEW; RISK ASSESSMENT; RISK FACTOR; SEIZURE; SINUS BRADYCARDIA; SUDDEN CARDIAC DEATH; SUPRAVENTRICULAR TACHYCARDIA; TACHYCARDIA; TORSADE DES POINTES;

EID: 84891759948     PISSN: 17358620     EISSN: 20082371     Source Type: Journal    
DOI: None     Document Type: Review

References (108)

1. Goodman J, Shimbo D, Haas DC, Davidson KW, Rieckmann N. Incident and recurrent major depressive disorder and coronary artery disease severity in acute coronary syndrome patients. J Psychiatr Res 2008;42:670-675.
2. Carney RM, Freedland KE. Depression in patients with coronary heart disease. Am J Med 2008;121:S20-27.
3. Whooley MA, Wong JM. Depression and cardiovascular disorders. Annu Rev Clin Psychol 2013;9:327-354.
4. Carney RM, Rich MW, Freedland KE, Saini J, teVelde A, Simeone C, Clark K. Major depressive disorder predicts cardiac events in patients with coronary artery disease. Psychosom Med 1988;50:627-633.
5. Bivanco-Lima D, de Souza Santos I, Vannucchi AM, de Almeida Ribeiro MC. Cardiovascular risk in individuals with depression. Rev Assoc Med Bras 2013;59:298-304.
6. Herrmann C, Brand-Driehorst S, Buss U, Rüger U. Effects of anxiety and depression on 5-year mortality in 5,057 patients referred for exercise testing. J Psychosom Res 2000;48:455-462.
7. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442.
8. Stafford L, Berk M, Reddy P, Jackson HJ. Comorbid depression and health-related quality of life in patients with coronary artery disease. J Psychosom Res 2007;62:401-410.
9. Chavez CA, Ski CF, Thompson DR. Depression and coronary heart disease: apprehending the elusive black dog. Int J Cardiol 2012;158:335-336.
10. Akhondzadeh S, Jafari S, Raisi F, Nasehi AA, Ghoreishi A, Salehi B, Mohebbi-Rasa S, Raznahan M, Kamalipour A. Clinical trial of adjunctive celecoxib treatment in patients with major depression: a double blind and placebo controlled trial. Depress Anxiety 2009;26:607-611.
11. Abolfazli R, Hosseini M, Ghanizadeh A, Ghaleiha A, Tabrizi M, Raznahan M, Golalizadeh M, Akhondzadeh S. Double-blind randomized parallel-group clinical trial of effcacy of the combination fuoxetine plus modafnil versus fuoxetine plus placebo in the treatment of major depression. Depress Anxiety 2011;28:297-302.
12. Abbasi SH, Hosseini F, Modabbernia A, Ashraf M, Akhondzadeh S. Effect of celecoxib add-on treatment on symptoms and serum IL-6 concentrations in patients with major depressive disorder: randomized double-blind placebo-controlled study. J Affect Disord 2012;141:308-314.
13. Olfson M, Marcus SC. National patterns in antidepressant medication treatment. Arch Gen Psychiatry 2009;66:848-856.
14. Akhondzadeh S, Faraji H, Sadeghi M, Afkham K, Fakhrzadeh H, Kamalipour A. Double-blind comparison of fuoxetine and nortriptyline in the treatment of moderate to severe major depression. J Clin Pharm Ther 2003;28:379-384.
15. Marano G, Traversi G, Romagnoli E, Catalano V, Lotrionte M, Abbate A, Biondi-Zoccai G, Mazza M. Cardiologic side effects of psychotropic drugs. J Geriatr Cardiol 2011;8:243-253.
16. Hamer M, David Batty G, Seldenrijk A, Kivimaki M. Antidepressant medication use and future risk of cardiovascular disease: the Scottish Health Survey. Eur Heart J 2011;32:437-442.
17. Waring WS. Clinical use of antidepressant therapy and associated cardiovascular risk. Drug Healthc Patient Saf 2012;4:93-101.
18. Leonard CE, Bilker WB, Newcomb C, Kimmel SE, Hennessy S. Antidepressants and the risk of sudden cardiac death and ventricular arrhythmia. Pharmacoepidemiol Drug Saf 2011;20:903-913.
19. Wimbiscus M, Kostenko O, Malone D. MAO inhibitors: risks, benefts, and lore. Cleve Clin J Med 2010;77:859-882.
20. Riederer P, Lachenmayer L, Laux G. Clinical applications of MAO-inhibitors. Curr Med Chem 2004;11:2033-2043.
21. Lavin MR, Mendelowitz A, Kronig MH. Spontaneous hypertensive reactions with monoamine oxidase inhibitors. Biol Psychiatry 1993;34:146-151.
22. O'Brien S, McKeon P, O'Regan M, O'Flaherty A, Patel R. Blood pressure effects of tranylcypromine when prescribed singly and in combination with amitriptyline. J Clin Psychopharmacol 1992;12:104-109.
23. Waring WS, Wallace WA. Acute myocarditis after massive phenelzine overdose. Eur J Clin Pharmacol 2007;63:1007-1009.
24. Downes MA, Whyte IM, Isbister GK. QTc abnormalities in deliberate self-poisoning with moclobemide. Intern Med J 2005;35:388-391.
25. Glassman AH, Pardell R, Woodring S. Cardiovascular effects of the standard tricyclic antidepressants. Clin Chem 1988;34:856-858.
26. Pacher P, Ungvari Z, Nanasi PP, Furst S, Kecskemeti V. Speculations on difference between tricyclic and selective serotonin reuptake inhibitor antidepressants on their cardiac effects. Is there any? Curr Med Chem 1999;6:469-480.
27. Pacher P, Kecskemeti V. Cardiovascular side effects of new antidepressants and antipsychotics: new drugs, old concerns? Curr Pharm Des 2004;10:2463-2475.
28. Glassman AH. Cardiovascular effects of tricyclic antidepressants. Annu Rev Med 1984;35:503-511.
29. Vohra J, Burrows G, Hunt D, Sloman G. The effect of toxic and therapeutic doses of tricyclic antidepressant drugs on intracardiac conduction. Eur J Cardiol 1975;3:219-227.
30. Roose SP, Glassman AH, Giardina EG, Walsh BT, Woodring S, Bigger JT. Tricyclic antidepressants in depressed patients with cardiac conduction disease. Arch Gen Psychiatry 1987;44:273-275.
31. Glassman AH, Roose SP, Bigger JT, Jr. The safety of tricyclic antidepressants in cardiac patients. Risk-beneft reconsidered. JAMA 1993;269:2673-2675.
32. Crome P, Newman B. Fatal tricyclic antidepressant poisoning. J R Soc Med 1979;72:649-653.
33. Hultén BA. TCA poisoning treated in the intensive care unit. Pharmacopsychiatry 1990;23:14-16.
34. Sala M, Lazzaretti M, De Vidovich G, Caverzasi E, Barale F, d'Allio G, Brambilla P. Electrophysiological changes of cardiac function during antidepressant treatment. Ther Adv Cardiovasc Dis 2009;3:29-43.
35. Thanacoody HK, Thomas SH. Tricyclic antidepressant poisoning: cardiovascular toxicity. Toxicol Rev 2005;24:205-214.
36. Rodriguez de la Torre B, Dreher J, Malevany I, Bagli M, Kolbinger M, Omran H, Lüderitz B, Rao ML. Serum levels and cardiovascular effects of tricyclic antidepressants and selective serotonin reuptake inhibitors in depressed patients. Ther Drug Monit 2001;23:435-440.
37. Fernandez A, Bang SE, Srivathsan K, Vieweg WV. Cardiovascular side effects of newer antidepressants. Anadolu Kardiyol Derg 2007;7:305-309.
38. Tarabar AF, Hoffman RS, Nelson L. Citalopram overdose: late presentation of torsades de pointes (TdP) with cardiac arrest. J Med Toxicol 2008;4:101-105.
39. Mohammed R, Norton J, Geraci SA, Newman DB, Koch CA. Prolonged QTc interval due to escitalopram overdose. J Miss State Med Assoc 2010;51:350-353.
40. Digby G, Machaalany J, Malik P, Methot M, Simpson CS, Redfearn D, Baranchuk A. Multifactorial QT interval prolongation. Cardiol J 2010;17:184-188.
41. Wenzel-Seifert K, Wittmann M, Haen E. Torsade de Pointes episodes under treatment with selective serotonin reuptake inhibitors. Pharmacopsychiatry 2010;43:279-281.
42. de Abajo FJ. Effects of selective serotonin reuptake inhibitors on platelet function: mechanisms, clinical outcomes and implications for use in elderly patients. Drugs Aging 2011;28:345-367.
43. Kharofa J, Sekar P, Haverbusch M, Moomaw C, Flaherty M, Kissela B, Broderick J, Woo D. Selective serotonin reuptake inhibitors and risk of hemorrhagic stroke. Stroke 2007;38:3049-3051.
44. Parissis JT, Fountoulaki K, Filippatos G, Adamopoulos S, Paraskevaidis I, Kremastinos D. Depression in coronary artery disease: novel pathophysiologic mechanisms and therapeutic implications. Int J Cardiol 2007;116:153-160.
45. Ceylan ME, Alpsan-Omay MH. Bleeding induced by SSRIs. Eur Psychiatry 2005;20:570-571.
46. Cherin P, Colvez A, Deville de Periere G, Sereni D. Risk of syncope in the elderly and consumption of drugs: a case-control study. J Clin Epidemiol 1997;50:313-320.
47. Deshmukh A, Ulveling K, Alla V, Abuissa H, Airey K. Prolonged QTc interval and torsades de pointes induced by citalopram. Tex Heart Inst J 2012;39:68-70.
48. Goldberg RJ. Selective serotonin reuptake inhibitors: infrequent medical adverse effects. Arch Fam Med 1998;7:78-84.
49. Fricchione GL, Woznicki RM, Klesmer J, Vlay SC. Vasoconstrictive effects and SSRIs. J Clin Psychiatry 1993;54:71-72.
50. Açikalin A, Satar S, Avc A, Topal M, Kuvandk G, Sebe A. QTc intervals in drug poisoning patients with tricyclic antidepressants and selective serotonin reuptake inhibitors. Am J Ther 2010;17:30-33.
51. Cooke MJ, Waring WS. Citalopram and cardiac toxicity. Eur J Clin Pharmacol 2013;69:755-760.
52. Personne M, Persson H, Sjöberg E. Citalopram toxicity. Lancet 1997;350:518-519.
53. Personne M, Sjöberg G, Persson H. Citalopram overdose--review of cases treated in Swedish hospitals. J Toxicol Clin Toxicol 1997;35:237-240.
54. Grundemar L, Wohlfart B, Lagerstedt C, Bengtsson F, Eklundh G. Symptoms and signs of severe citalopram overdose. Lancet 1997;349:1602.
55. Snider RD. Case report: left bundle branch block--a rare complication of citalopram overdose. J S C Med Assoc 2001;97:380-382.
56. Rothenhäusler HB, Hoberl C, Ehrentrout S, Kapfhammer HP, Weber MM. Suicide attempt by pure citalopram overdose causing long-lasting severe sinus bradycardia, hypotension and syncopes: successful therapy with a temporary pacemaker. Pharmacopsychiatry 2000;33:150-152.
57. Engebretsen KM, Harris CR, Wood JE. Cardiotoxicity and late onset seizures with citalopram overdose. J Emerg Med 2003;25:163-166.
58. Howell C, Wilson AD, Waring WS. Cardiovascular toxicity due to venlafaxine poisoning in adults: a review of 235 consecutive cases. Br J Clin Pharmacol 2007;64:192-197.
59. Mbaya P, Alam F, Ashim S, Bennett D. Cardiovascular effects of high dose venlafaxine XL in patients with major depressive disorder. Hum Psychopharmacol 2007;22:129-133.
60. Letsas K, Korantzopoulos P, Pappas L, Evangelou D, Efremidis M, Kardaras F. QT interval prolongation associated with venlafaxine administration. Int J Cardiol 2006;109:116-117.
61. Fleishaker JC, Francom SF, Herman BD, Knuth DW, Azie NE. Lack of effect of reboxetine on cardiac repolarization. Clin Pharmacol Ther 2001;70:261-269.
62. LoVecchio F, Riley B, Pizon A, Brown M. Outcomes after isolated mirtazapine (Remeron) supratherapeutic ingestions. J Emerg Med 2008;34:77-78.
63. Amini H, Aghayan S, Jalili SA, Akhondzadeh S, Yahyazadeh O, Pakravan-Nejad M. Comparison of mirtazapine and fuoxetine in the treatment of major depressive disorder: a double-blind, randomized trial. J Clin Pharm Ther 2005;30:133-138.
64. Service JA, Waring WS. QT Prolongation and delayed atrioventricular conduction caused by acute ingestion of trazodone. Clin Toxicol (Phila) 2008;46:71-73.
65. Fagiolini A, Comandini A, Catena Dell'Osso M, Kasper S. Rediscovering trazodone for the treatment of major depressive disorder. CNS Drugs 2012;26:1033-1049.
66. Gintant G. An evaluation of hERG current assay performance: Translating preclinical safety studies to clinical QT prolongation. Pharmacol Ther 2011;129:109-119.
67. Alvarez W, Jr, Pickworth KK. Safety of antidepressant drugs in the patient with cardiac disease: a review of the literature. Pharmacotherapy 2003;23:754-771.
68. Roose SP, Glassman AH. Antidepressant choice in the patient with cardiac disease: lessons from the Cardiac Arrhythmia Suppression Trial (CAST) studies. J Clin Psychiatry 1994;55 Suppl A:83-87.
69. Stöllberger C, Huber JO, Finsterer J. Antipsychotic drugs and QT prolongation. Int Clin Psychopharmacol 2005;20:243-251.
70. Morganroth J, Brozovich FV, McDonald JT, Jacobs RA. Variability of the QT measurement in healthy men, with implications for selection of an abnormal QT value to predict drug toxicity and proarrhythmia. Am J Cardiol 1991;67:774-776.
71. Del Rosario ME, Weachter R, Flaker GC. Drug-induced QT prolongation and sudden death. Mo Med 2010;107:53-58.
72. Olsen KM. Pharmacologic agents associated with QT interval prolongation. J Fam Pract 2005;Suppl:S8-S14.
73. Goodnick PJ, Jerry J, Parra F. Psychotropic drugs and the ECG: focus on the QTc interval. Expert Opin Pharmacother 2002;3:479-498.
74. Alvarez PA, Pahissa J. QT alterations in psychopharmacology: proven candidates and suspects. Curr Drug Saf 2010;5:97-104.
75. Vieweg WV, Wood MA, Fernandez A, Beatty-Brooks M, Hasnain M, Pandurangi AK. Proarrhythmic risk with antipsychotic and antidepressant drugs: implications in the elderly. Drugs Aging 2009;26:997-1012.
76. Sauer AJ, Newton-Cheh C. Clinical and genetic determinants of torsade de pointes risk. Circulation 2012;125:1684-1694.
77. Kallergis EM, Goudis CA, Simantirakis EN, Kochiadakis GE, Vardas PE. Mechanisms, risk factors, and management of acquired long QT syndrome: a comprehensive review. Scientifc World Journal 2012;2012:212178.
78. Min KB, Min JY, Paek D, Cho SI. The impact of the components of metabolic syndrome on heart rate variability: using the NCEP-ATP III and IDF defnitions. Pacing Clin Electrophysiol 2008;31:584-591.
79. No authors listed. Standards of measurement, physiological interpretation, and clinical use. Task Force of the European Society of Cardiology and the North American Society of Pacing and Electrophysiology. Eur Heart J 1996;17:354-381.
80. Buckley NA, Chevalier S, Leditschke IA, O'Connell DL, Leitch J, Pond SM. The limited utility of electrocardiography variables used to predict arrhythmia in psychotropic drug overdose. Crit Care 2003;7:R101-107.
81. Bigger JT, Jr, Kleiger RE, Fleiss JL, Rolnitzky LM, Steinman RC, Miller JP. Components of heart rate variability measured during healing of acute myocardial infarction. Am J Cardiol 1988;61:208-215.
82. Grippo AJ, Johnson AK. Biological mechanisms in the relationship between depression and heart disease. Neurosci Biobehav Rev 2002;26:941-962.
83. Thayer JF, Lane RD. The role of vagal function in the risk for cardiovascular disease and mortality. Biol Psychol 2007;74:224-242.
84. van der Kooy KG, van Hout HP, van Marwijk HW, de Haan M, Stehouwer CD, Beekman AT. Differences in heart rate variability between depressed and non-depressed elderly. Int J Geriatr Psychiatry 2006;21:147-150.
85. Udupa K, Sathyaprabha TN, Thirthalli J, Kishore KR, Lavekar GS, Raju TR, Gangadhar BN. Alteration of cardiac autonomic functions in patients with major depression: a study using heart rate variability measures. Affect Disord 2007;100:137-141.
86. Kemp AH, Quintana DS, Gray MA, Felmingham KL, Brown K, Gatt JM. Impact of depression and antidepressant treatment on heart rate variability: a review and meta-analysis. Biol Psychiatry 2010;67:1067-1074.
87. Waring WS, Rhee JY, Bateman DN, Leggett GE, Jamie H. Impaired heart rate variability and altered cardiac sympathovagal balance after antidepressant overdose. Eur J Clin Pharmacol 2008;64:1037-1041.
88. Jakobsen J, Hauksson P, Vestergaard P. Heart rate variation in patients treated with antidepressants. An index of anticholinergic effects? Psychopharmacology (Berl) 1984;84:544-548.
89. Glassman AH, Bigger JT, Gaffney M, Van Zyl LT. Heart rate variability in acute coronary syndrome patients with major depression: infuence of sertraline and mood improvement. Arch Gen Psychiatry 2007;64:1025-1031.
90. Lederbogen F, Gernoth C, Weber B, Colla M, Kniest A, Heuser I, Deuschle M. Antidepressive treatment with amitriptyline and paroxetine: comparable effects on heart rate variability. J Clin Psychopharmacol 2001;21:238-239.
91. Rutledge T, Reis VA, Linke SE, Greenberg BH, Mills PJ. Depression in heart failure a meta-analytic review of prevalence, intervention effects, and associations with clinical outcomes. J Am Coll Cardiol 2006;48:1527-1537.
92. O'Connor CM, Jiang W, Kuchibhatla M, Mehta RH, Clary GL, Cuffe MS, Christopher EJ, Alexander JD, Califf RM, Krishnan RR. Antidepressant use, depression, and survival in patients with heart failure. Arch Intern Med 2008;168:2232-2237.
93. Vaccarino V, Kasl SV, Abramson J, Krumholz HM. Depressive symptoms and risk of functional decline and death in patients with heart failure. J Am Coll Cardiol 2001;38:199-205.
94. Gottlieb SS, Khatta M, Friedmann E, Einbinder L, Katzen S, Baker B, Marshall J, Minshall S, Robinson S, Fisher ML, Potenza M, Sigler B, Baldwin C, Thomas SA. The infuence of age, gender, and race on the prevalence of depression in heart failure patients. J Am Coll Cardiol 2004;43:1542-1549.
95. Jiang W, Krishnan R, Kuchibhatla M, Cuffe MS, Martsberger C, Arias RM, O'Connor CM; SADHART-CHF Investigators. Characteristics of depression remission and its relation with cardiovascular outcome among patients with chronic heart failure (from the SADHART-CHF Study). Am J Cardiol 2011;107:545-551.
96. Pizzi C, Rutjes AW, Costa GM, Fontana F, Mezzetti A, Manzoli L. Meta-analysis of selective serotonin reuptake inhibitors in patients with depression and coronary heart disease. Am J Cardiol 2011;107:972-979.
97. O'Connor CM, Jiang W, Kuchibhatla M, Silva SG, Cuffe MS, Callwood DD, Zakhary B, Stough WG, Arias RM, Rivelli SK, Krishnan R; SADHART-CHF Investigators. Safety and effcacy of sertraline for depression in patients with heart failure: results of the SADHART-CHF (Sertraline Against Depression and Heart Disease in Chronic Heart Failure) trial. J Am Coll Cardiol 2010;56:692-699.
98. Sherwood A, Blumenthal JA, Trivedi R, Johnson KS, O'Connor CM, Adams KF, Jr, Dupree CS, Waugh RA, Bensimhon DR, Gaulden L, Christenson RH, Koch GG, Hinderliter AL. Relationship of depression to death or hospitalization in patients with heart failure. Arch Intern Med 2007;167:367-373.
99. Fosbøl EL, Gislason GH, Poulsen HE, Hansen ML, Folke F, Schramm TK, Olesen JB, Bretler DM, Abildstrøm SZ, Sørensen R, Hvelplund A, Køber L, Torp-Pedersen C. Prognosis in heart failure and the value of {beta}-blockers are altered by the use of antidepressants and depend on the type of antidepressants used. Circ Heart Fail 2009;2:582-590.
100. Jiang W, Krishnan RR, O'Connor CM. Depression and heart disease: evidence of a link, and its therapeutic implications. CNS Drugs 2002;16:111-127.
101. Bush DE, Ziegelstein RC, Tayback M, Richter D, Stevens S, Zahalsky H, Fauerbach JA. Even minimal symptoms of depression increase mortality risk after acute myocardial infarction. Am J Cardiol 2001;88:337-341.
102. Cohen HW, Gibson G, Alderman MH. Alderman, Excess risk of myocardial infarction in patients treated with antidepressant medications: association with use of tricyclic agents. Am J Med 2000;108:2-8.
103. Regan KL. Depression treatment with selective serotonin reuptake inhibitors for the postacute coronary syndrome population: a literature review. J Cardiovasc Nurs 2008;23:489-496.
104. Maurer-Spurej E. Serotonin reuptake inhibitors and cardiovascular diseases: a platelet connection. Cell Mol Life Sci 2005;62:159-170.
105. Glassman AH, O'Connor CM, Califf RM, Swedberg K, Schwartz P, Bigger JT, Jr, Krishnan KR, van Zyl LT, Swenson JR, Finkel MS, Landau C, Shapiro PA, Pepine CJ, Mardekian J, Harrison WM, Barton D, Mclvor M; Sertraline Antidepressant Heart Attack Randomized Trial (SADHEART) Group. Sertraline treatment of major depression in patients with acute MI or unstable angina. JAMA 2002;288:701-709.
106. Lespérance F, Frasure-Smith N, Koszycki D, Laliberté MA, van Zyl LT, Baker B, Swenson JR, Ghatavi K, Abramson BL, Dorian P, Guertin MC; CREATE Investigators. Effects of citalopram and interpersonal psychotherapy on depression in patients with coronary artery disease: the Canadian Cardiac Randomized Evaluation of Antidepressant and Psychotherapy Effcacy (CREATE) trial JAMA 2007;297:367-379.
107. Strik JJ, Honig A, Lousberg R, Lousberg AH, Cheriex EC, Tuynman-Qua HG, Kuijpers PM, Wellens HJ, Van Praag HM. Effcacy and safety of fuoxetine in the treatment of patients with major depression after frst myocardial infarction: fndings from a double-blind, placebo-controlled trial. Psychosom Med 2000;62:783-789.
108. Taylor CB, Youngblood ME, Catellier D, Veith RC, Carney RM, Burg MM, Kaufmann PG, Shuster J, Mellman T, Blumenthal JA, Krishnan R, Jaffe AS; ENRICHD Investigators. Effects of antidepressant medication on morbidity and mortality in depressed patients after myocardial infarction. Arch Gen Psychiatry 2005;62:792-798.